Morphologic Response to PRRT According to Various Baseline Factors
Variable | Patients (n) | Regression* | P |
Total | 74 | 40 (54.1) | |
Age | |||
≤65 y | 35 | 18 (51.4) | 0.816 |
>65 y | 39 | 22 (56.4) | |
Tumor type | |||
P-NET | 33 | 24 (72.7) | 0.005 |
Other GEP NET | 41 | 16 (39.0) | |
Performance status | |||
KPS ≤ 70 | 27 | 13 (48.1) | 0.476 |
KPS > 70 | 47 | 27 (57.4) | |
Functionality | |||
Nonfunctional | 55 | 32 (58.2) | 0.289 |
Functional | 19 | 8 (42.1) | |
CgA | |||
≤600 ng/mL | 45 | 23 (51.1) | 0.634 |
>600 ng/mL | 29 | 17 (58.6) | |
NSE | |||
≤15 ng/mL | 39 | 23 (59.0) | 0.484 |
>15 ng/mL | 35 | 17 (48.6) | |
Ki-67 index | |||
≤10% | 60 | 32 (53.3) | 1.0 |
>10% | 14 | 8 (57.1) | |
≤2% (G1) | 26 | 13 (50.0) | 0.873 |
3%–10% (low-range G2) | 34 | 19 (55.9) | |
15%–20% (high-range G2) | 14 | 8 (57.1) | |
Tracer uptake | |||
≤ Grade 2 | 9 | 2 (22.2) | 0.071 |
> Grade 2 | 65 | 38 (58.5) |
↵* Regression (partial response or minor response) is reported as number of patients, with percentage in parentheses.
P-NET = pancreatic NET; CgA = chromogranin A.